近日，由中信建投资本管理有限公司（以下简称"中信建投资本"）与漳州片仔癀投资管理有限公司、漳州片仔癀资产经营有限公司、漳州市产业股权 投资有限公司、漳州高鑫发展有限公司、漳州市旅游投资集团有限公司、桐乡市金凤凰服务业发展集团有限公司、桐乡市华笙商业管理有限公司、桐 乡市产融桐富创业投资合伙企业（有限合伙）共同发起设立的漳州高鑫润信大健康产业投资合伙企业（有限合伙）（以下简称"漳州高鑫润信大健康 基金"）在中国证券投资基金业协会完成备案。 来源：中信建投资本 每日｜荐读 论坛： 2025母基金年度论坛圆满举办：内地携手香港，共话科创时代中国力量 荐读： 重新发现香港：科创时代的新蓝图 榜单： 「2025投资机构软实力排行榜」正式发布 热文： 今天，LP、GP都往厦门飞 漳州高鑫润信大健康基金由中信建投资本担任基金管理人、普通合伙人及执行事务合伙人。基金总规模10亿元，主要投资领域为医疗健康领域，包 含药品、医疗器械、医疗健康上游供应链及零部件、食品保健品、合成生物、化工材料、消费医疗等大健康相关赛道，对非上市企业（重点关注成长 期以及早期创业投资项目）进行股权投资。 ...

Fund Overview - The fund is named "TaiKang National Public Health and Medical Health Exchange-Traded Open-Ended Index Securities Investment Fund" and is managed by TaiKang Fund Management Co., Ltd. [2] - The fund's main code is 159760, and it was established on December 6, 2021, with trading commencing on December 20, 2021 [2]. - The fund aims to closely track the performance of its benchmark index, the National Public Health and Health Index, with a goal of minimizing tracking deviation and error [2][3]. Financial Performance - As of June 30, 2025, the fund's total net asset value was approximately 80.06 million RMB, with a net asset value per share of 0.5871 RMB [3][19]. - The fund reported a realized loss of approximately 11.16 million RMB for the period, with a profit of 1.25 million RMB [3][19]. - The weighted average net profit rate for the period was 1.50%, and the net value growth rate was 1.63% [3][19]. Investment Strategy - The fund primarily employs a full replication strategy to construct its stock investment portfolio based on the composition and weight of the benchmark index [2][11]. - The fund may also invest in fixed-income instruments to ensure liquidity and enhance investment returns [2][11]. - The fund's investment strategy includes hedging through stock index futures to improve investment efficiency while controlling risks [2][11]. Market Context - The macroeconomic environment in the first half of 2025 showed structural differentiation, with resilience in certain sectors like exports and manufacturing, while real estate cooled down after an initial recovery [10][14]. - The overall equity market experienced fluctuations, with the Shanghai Composite Index rising by 2.76% and the Hang Seng Index increasing by 20.18% during the same period [10][14]. - The pharmaceutical sector is expected to benefit from a series of policy incentives aimed at supporting the development of innovative drugs, marking a significant opportunity for investment in this area [14][10]. Management and Compliance - TaiKang Fund Management Co., Ltd. has been compliant with relevant laws and regulations, ensuring fair treatment of all funds under its management [9][10]. - The fund management has established a fair trading system and monitoring processes to prevent any conflicts of interest [9][10]. - The fund's valuation process is overseen by a dedicated valuation team, ensuring transparency and adherence to regulatory standards [14][15].